Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ) is now available.
Shanghai Haohai Biological Technology announced the finalisation of profit guarantee arrangements tied to its staged acquisition of Shenzhen New Industries Material of Ophthalmology Co., Ltd., in which its wholly owned subsidiary agreed to buy equity interests from several investment partners and individuals. The deal structure included a three-year profit guarantee for 2023–2025, under which the sellers were obliged to compensate the buyer if the ophthalmology target’s actual profits fell short of agreed thresholds.
Audited results show the target exceeded its 2023 profit guarantee but missed the significantly higher targets for 2024 and 2025, triggering monetary compensation obligations to Shanghai Haohai’s subsidiary. The parties agreed that total compensation of about RMB57.9 million, arising from the shortfall years, would be fully offset against the RMB74 million consideration payable, effectively settling the obligation and leaving a residual amount still payable to the sellers, with independent directors confirming the connected parties have fulfilled their contractual duties.
The most recent analyst rating on (HK:6826) stock is a Buy with a HK$28.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. is a PRC-incorporated biopharmaceutical and medical technology group listed in Hong Kong. Through subsidiaries such as Shanghai Haohai Medical Technology Development Co., Ltd., it focuses on ophthalmology-related materials and products, including its investment in Shenzhen New Industries Material of Ophthalmology Co., Ltd., to strengthen its position in the medical and eye-care markets.
Average Trading Volume: 141,921
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$10.01B
Find detailed analytics on 6826 stock on TipRanks’ Stock Analysis page.